title: The future of transcatheter pulmonary valvulation.
abstract: Percutaneous pulmonary valve implantation now has a key role in the setting of dysfunctional right ventricle-to-pulmonary artery conduits or failing bioprosthetic pulmonary valves. However, despite the excellent results obtained with the two devices available currently (the Melody(®) valve [Medtronic Inc., Minneapolis, MN, USA] and the Edwards SAPIEN(®) valve [Edwards Lifesciences, Irvine, CA, USA]), many patients eligible for pulmonary valve replacement remain unsuitable for percutaneous pulmonary valve implantation, mainly because of large native outflow tracts. Accordingly, one of the major challenges for the future is to expand percutaneous pulmonary valve implantation to a broader population of patients. Moving forward, there is important ongoing research that is intended to improve patient outcomes, expand percutaneous pulmonary valve implantation therapy and continue to reduce the number of open-heart surgeries in this population. In this review, we underline the limitations and issues associated with the devices available currently, and we focus on the development of new strategies (such as hybrid approaches or magnetic resonance-guided procedures), new devices (such as right ventricular outflow tract reducers or the novel Native Outflow Tract valved stent from Medtronic) and new technologies (such as tissue-engineered valves), which may help to take up these challenges and represent the future of transcatheter valve implantation.
authors.affiliation: Groupe de cathétérisme interventionnel pédiatrique et congénitale (GCIPC), filiale de cardiologie pédiatrique et congénitale de la Société française de cardiologie, 75015 Paris, France; University Hospital of Bordeaux, Department of Paediatric and Adult Congenital Heart Defects, 33604 Pessac, France.
authors.forename: Zakaria
authors.initials: Z
authors.lastname: Jalal
authors.affiliation: Groupe de cathétérisme interventionnel pédiatrique et congénitale (GCIPC), filiale de cardiologie pédiatrique et congénitale de la Société française de cardiologie, 75015 Paris, France; University Hospital of Bordeaux, Department of Paediatric and Adult Congenital Heart Defects, 33604 Pessac, France; Université Victor-Segalen, 33076 Bordeaux, France.
authors.forename: Jean-Benoit
authors.initials: JB
authors.lastname: Thambo
authors.affiliation: Groupe de cathétérisme interventionnel pédiatrique et congénitale (GCIPC), filiale de cardiologie pédiatrique et congénitale de la Société française de cardiologie, 75015 Paris, France; Centre de référence malformations cardiaques congénitales complexes, M3C, Necker Hospital for Sick Children, Assistance Publique des Hôpitaux de Paris, Paediatric Cardiology, 75015 Paris, France; Université Paris Descartes, Sorbonne Paris Cité, 75006 Paris, France. Electronic address: younes.boudjemline@nck.aphp.fr.
authors.forename: Younes
authors.initials: Y
authors.lastname: Boudjemline
mesh_terms: D001705:Bioprosthesis / Q000639:trends; D006328:Cardiac Catheterization / Q000009:adverse effects / Q000295:instrumentation / Q000379:methods / Q000639:trends*; D005544:Forecasting; D006330:Heart Defects, Congenital / Q000601:surgery*; D006350:Heart Valve Prosthesis / Q000639:trends; D019918:Heart Valve Prosthesis Implantation / Q000009:adverse effects / Q000295:instrumentation / Q000379:methods / Q000639:trends*; D006801:Humans; D011474:Prosthesis Design; D011475:Prosthesis Failure; D011664:Pulmonary Valve / Q000503:physiopathology / Q000601:surgery*; D011665:Pulmonary Valve Insufficiency / Q000175:diagnosis / Q000503:physiopathology / Q000628:therapy*; D011666:Pulmonary Valve Stenosis / Q000175:diagnosis / Q000503:physiopathology / Q000628:therapy*; D012307:Risk Factors; D016896:Treatment Outcome
keywords: Cardiopathies congénitales; Congenital heart disease; Melody(®); Melody(®) valve; Percutaneous pulmonary valve implantation; Remplacement valvulaire pulmonaire percutané